|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Abbott |
|---|---|
| Information provided by: | Abbott |
| ClinicalTrials.gov Identifier: | NCT00002036 |
Purpose
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Anti-HIV Immune Serum Globulin (Human) |
Phase I |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Primary Purpose: Treatment |
| Official Title: | Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Required with a diagnosis of AIDS:
Active substance abuse.
Contacts and Locations
More Information
| Study ID Numbers: | 060A, 0001-008 |
| Study First Received: | November 2, 1999 |
| Last Updated: | February 19, 2009 |
| ClinicalTrials.gov Identifier: | NCT00002036 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Acquired Immunodeficiency Syndrome AIDS-Related Complex Immunization, Passive |
|
RNA Virus Infections Sexually Transmitted Diseases, Viral Slow Virus Diseases Immune System Diseases Immunologic Factors Physiological Effects of Drugs Acquired Immunodeficiency Syndrome Pharmacologic Actions |
Immunologic Deficiency Syndromes Immune Sera Virus Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections |